Philogen SpADUS Philogen Stock Report

Philogen SpA engages engineering and clinical development of lead products capable of targeting angiogenesis. The company is headquartered in Sovicille, Siena and currently employs 135 full-time employees. The company went IPO on 2021-03-03. The firm develops products and technologies for the diagnosis and therapy of serious human diseases. The company has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The firm's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.